{"id":"https://openalex.org/W4389450141","doi":"https://doi.org/10.1212/wnl.96.15_supplement.1937","title":"Peripheral Neurological Safety of Subcutaneous Tanezumab versus Placebo or NSAIDs in Patients with Osteoarthritis. (1937)","display_name":"Peripheral Neurological Safety of Subcutaneous Tanezumab versus Placebo or NSAIDs in Patients with Osteoarthritis. (1937)","publication_year":2021,"publication_date":"2021-04-13","ids":{"openalex":"https://openalex.org/W4389450141","doi":"https://doi.org/10.1212/wnl.96.15_supplement.1937"},"language":"en","primary_location":{"id":"doi:10.1212/wnl.96.15_supplement.1937","doi":"https://doi.org/10.1212/wnl.96.15_supplement.1937","is_oa":false,"landing_page_url":"https://doi.org/10.1212/wnl.96.15_supplement.1937","pdf_url":null,"source":{"id":"https://openalex.org/S79704628","display_name":"Neurology","issn_l":"0028-3878","issn":["0028-3878","1526-632X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Neurology","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5102834751","display_name":"Mark T. Brown","orcid":"https://orcid.org/0000-0002-9618-2480","observed_orcids":["https://orcid.org/0000-0002-9618-2480"]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mark T. Brown","raw_affiliation_strings":["Pfizer Inc"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer Inc","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5070172721","display_name":"Paola Sandroni","orcid":"https://orcid.org/0000-0001-7618-9661","observed_orcids":["https://orcid.org/0000-0001-7618-9661"]},"institutions":[{"id":"https://openalex.org/I1330342723","display_name":"Mayo Clinic","ror":"https://ror.org/02qp3tb03","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1330342723"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Paola Sandroni","raw_affiliation_strings":["Mayo Clinic"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Mayo Clinic","institution_ids":["https://openalex.org/I1330342723"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109264449","display_name":"Kenneth C. Gorson","orcid":"https://orcid.org/0000-0003-4955-1324","observed_orcids":["https://orcid.org/0000-0003-4955-1324"]},"institutions":[{"id":"https://openalex.org/I3018163063","display_name":"St. Elizabeth's Medical Center","ror":"https://ror.org/00cr15z55","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I3018163063"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kenneth C. Gorson","raw_affiliation_strings":["St. Elizabeth\u2019s Medical Center"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"St. Elizabeth\u2019s Medical Center","institution_ids":["https://openalex.org/I3018163063"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5047373167","display_name":"Phillip A. Low","orcid":"https://orcid.org/0000-0002-5386-4764","observed_orcids":["https://orcid.org/0000-0002-5386-4764"]},"institutions":[{"id":"https://openalex.org/I1330342723","display_name":"Mayo Clinic","ror":"https://ror.org/02qp3tb03","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1330342723"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Phillip A. Low","raw_affiliation_strings":["Mayo Clinic"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Mayo Clinic","institution_ids":["https://openalex.org/I1330342723"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5080921373","display_name":"David John Hunter","orcid":"https://orcid.org/0000-0003-3197-752X","observed_orcids":["https://orcid.org/0000-0003-3197-752X"]},"institutions":[{"id":"https://openalex.org/I129604602","display_name":"The University of Sydney","ror":"https://ror.org/0384j8v12","country_code":"AU","type":"education","lineage":["https://openalex.org/I129604602"]}],"countries":["AU"],"is_corresponding":false,"raw_author_name":"David J. Hunter","raw_affiliation_strings":["The University of Sydney"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The University of Sydney","institution_ids":["https://openalex.org/I129604602"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5020898892","display_name":"Glenn C. Pixton","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Glenn C. Pixton","raw_affiliation_strings":["Pfizer Inc"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer Inc","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5016256502","display_name":"Robert J. Fountaine","orcid":"https://orcid.org/0000-0002-4105-1248","observed_orcids":["https://orcid.org/0000-0002-4105-1248"]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Robert J. Fountaine","raw_affiliation_strings":["Pfizer Inc"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer Inc","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5090431664","display_name":"Lars Viktrup","orcid":"https://orcid.org/0000-0002-8739-0544","observed_orcids":["https://orcid.org/0000-0002-8739-0544"]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Lars Viktrup","raw_affiliation_strings":["Eli Lilly and Company"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Eli Lilly and Company","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Elizabeth Johnston","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Elizabeth Johnston","raw_affiliation_strings":["Eli Lilly and Company"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Eli Lilly and Company","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5089760100","display_name":"Christine R. West","orcid":"https://orcid.org/0000-0001-9447-2911","observed_orcids":["https://orcid.org/0000-0001-9447-2911"]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Christine R. West","raw_affiliation_strings":["Pfizer Inc"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer Inc","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5084258579","display_name":"Kenneth M. Verburg","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kenneth M. Verburg","raw_affiliation_strings":["Pfizer Inc"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer Inc","institution_ids":["https://openalex.org/I180857899"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":5,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.3009338,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"96","issue":"15_supplement","first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10196","display_name":"Pain Mechanisms and Treatments","score":0.4081999957561493,"subfield":{"id":"https://openalex.org/subfields/2737","display_name":"Physiology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10196","display_name":"Pain Mechanisms and Treatments","score":0.4081999957561493,"subfield":{"id":"https://openalex.org/subfields/2737","display_name":"Physiology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10105","display_name":"Osteoarthritis Treatment and Mechanisms","score":0.30979999899864197,"subfield":{"id":"https://openalex.org/subfields/2745","display_name":"Rheumatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11752","display_name":"Cancer Treatment and Pharmacology","score":0.0640999972820282,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/tanezumab","display_name":"tanezumab","score":1.0},{"id":"https://openalex.org/keywords/peripheral-neuropathy","display_name":"peripheral neuropathy","score":0.7419999837875366},{"id":"https://openalex.org/keywords/osteoarthritis","display_name":"osteoarthritis","score":0.8960000276565552},{"id":"https://openalex.org/keywords/subcutaneous-administration","display_name":"subcutaneous administration","score":0.8529999852180481},{"id":"https://openalex.org/keywords/nonsteroidal-anti-inflammatory-drugs","display_name":"nonsteroidal anti-inflammatory drugs","score":0.9710000157356262},{"id":"https://openalex.org/keywords/drug-safety","display_name":"drug safety","score":0.7490000128746033},{"id":"https://openalex.org/keywords/neuropathic-pain","display_name":"neuropathic pain","score":0.6079999804496765}],"concepts":[{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.8066222667694092},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6789933443069458},{"id":"https://openalex.org/C2776164576","wikidata":"https://www.wikidata.org/wiki/Q62736","display_name":"Osteoarthritis","level":3,"score":0.5826552510261536},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.3442087769508362},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.15190184116363525},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.10118794441223145}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1212/wnl.96.15_supplement.1937","doi":"https://doi.org/10.1212/wnl.96.15_supplement.1937","is_oa":false,"landing_page_url":"https://doi.org/10.1212/wnl.96.15_supplement.1937","pdf_url":null,"source":{"id":"https://openalex.org/S79704628","display_name":"Neurology","issn_l":"0028-3878","issn":["0028-3878","1526-632X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Neurology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4212892514","https://openalex.org/W4384626231","https://openalex.org/W3034802231","https://openalex.org/W3162702690","https://openalex.org/W3156808925","https://openalex.org/W2060485806","https://openalex.org/W1525968286","https://openalex.org/W3126946716","https://openalex.org/W4229456992","https://openalex.org/W3033193276"],"abstract_inverted_index":{"Objective:":[0],"To":[1],"evaluate":[2],"the":[3,138,158,162,189,195,208,224,228,343,367,392,416,446],"peripheral":[4,33],"nerve":[5,25,121],"safety":[6,122],"of":[7,41,86,126,129,134,144,155,179,188,204,212,221,241,250,257,262,271,283,290,315,345,369,394,418,448,474,498,524,562,592],"subcutaneous":[8],"(SC)":[9],"tanezumab":[10,43,72,88,110,165,196,229,286],"versus":[11,44,89],"placebo":[12,45,163,277],"or":[13,112,117,278,323,353,377,402,426,456,481,506,531,542,572,601],"nonsteroidal":[14],"anti-inflammatory":[15],"drugs":[16],"(NSAIDs).":[17],"Background:":[18],"Tanezumab,":[19],"an":[20,66,95,202,313,324,472,482,496,507,522,532,543,560,573,590,602],"analgesic":[21],"monoclonal":[22],"antibody":[23],"against":[24],"growth":[26],"factor,":[27],"has":[28,306,320,332,338,362,387,411,435,441,465,478,489,503,515,528,539,553,569,583,598],"been":[29],"associated":[30],"with":[31,65,98,276],"abnormal":[32],"sensation":[34],"(APS)":[35],"in":[36,94,161,183,194,227,285,296,301,342,366,391,415,445],"prior":[37],"studies.":[38],"Design/Methods:":[39],"Safety":[40,85,355,379,404,428,458],"SC":[42,87,140],"was":[46,92],"assessed":[47],"using":[48],"pooled":[49,139],"data":[50],"from":[51,327,485,510,535,546,576,605],"3":[52],"osteoarthritis":[53,96],"trials":[54],"(NCT01089725,":[55],"NCT02697773":[56],"and":[57,77,83,103,153,172,219,234,248,269,298],"NCT02709486).":[58],"Treatments":[59],"(every":[60],"8-weeks":[61],"for":[62,148,216,245,266,310,347,358,371,382,396,407,420,431,450,461,469,493,519,557,587],"16\u201324":[63],"weeks":[64],"8\u201324":[67],"week":[68,80],"follow-up)":[69],"included":[70,124],"placebo,":[71],"2.5mg,":[73],"2.5mg":[74,111,166,230],"at":[75,79],"baseline":[76],"5mg":[78,82,113,170,197,232],"8,":[81],"10mg.":[84],"oral":[90],"NSAIDs":[91],"evaluated":[93],"trial":[97],"a":[99,104,127,280,350,374,399,423,453],"56-week":[100],"treatment":[101,159,225],"period":[102,160,226],"24-week":[105],"follow-up":[106],"(NCT02528188).":[107],"Patients":[108],"received":[109,307,321,339,363,388,412,442,466,479,490,504,516,529,540,554,570,584,599],"every":[114],"8":[115],"weeks,":[116],"twice-daily":[118],"NSAIDs.":[119],"Peripheral":[120],"assessments":[123],"use":[125],"group":[128,198],"27":[130],"adverse":[131],"events":[132],"(AEs)":[133],"APS.":[135],"Results:":[136],"In":[137,207],"placebo-controlled":[141],"studies,":[142,190],"AEs":[143,178,211,240,256,289],"APS":[145,180,205,213,242,258],"were":[146,181,214,243,264,293],"reported":[147,215,244,265],"2.2%,":[149],"5.1%,":[150],"3.2%,":[151],"6.1%":[152],"12.8%":[154],"patients":[156,222,284],"during":[157,223],"(n=586),":[164],"(n=602),":[167],"2.5/5mg":[168],"(n=219),":[169],"(n=347)":[171],"10mg":[173],"(n=86)":[174],"groups,":[175,237],"respectively.":[176,238,252,273],"All":[177],"mild/moderate":[182,295],"severity.":[184],"Up":[185],"to":[186,201,255,260,334,437],"end":[187,261],"1":[191],"patient":[192],"(0.3%)":[193],"discontinued":[199],"due":[200,254],"AE":[203],"(hypoesthesia).":[206],"NSAID-controlled":[209],"study,":[210],"6.2%,":[217],"9.0%":[218],"4.6%":[220],"(n=1002),":[231],"(n=998)":[233],"NSAID":[235],"(n=996)":[236],"Severe":[239],"0.1%,":[246],"0.3%":[247],"0.1%":[249],"patients,":[251,272],"Discontinuations":[253],"up":[259],"study":[263],"0.4%,":[267],"1.5%":[268],"0.4%":[270],"Conclusions:":[274],"Compared":[275],"NSAID,":[279],"higher":[281],"proportion":[282],"groups":[287],"had":[288],"APS;":[291],"these":[292],"typically":[294],"severity":[297],"rarely":[299],"resulted":[300],"discontinuation.":[302],"Disclosure:":[303],"Dr.":[304,318,330,336,360,385,409,433],"Brown":[305,319],"personal":[308,340,364,389,413,443,467,491,517,555,585],"compensation":[309,341,365,390,414,444,468,492,518,556,586],"serving":[311,348,372,397,421,451,470,494,520,558,588],"as":[312,471,495,521,559,589],"employee":[314,473,497,523,561,591],"Pfizer":[316,328,563,577],"Inc.":[317,329,500,512,564,578],"stock":[322,480,505,530,541,571,600],"ownership":[325,483,508,533,544,574,603],"interest":[326,484,509,534,545,575,604],"Sandroni":[331],"nothing":[333,436],"disclose.":[335,438],"Gorson":[337,361,386,410],"range":[344,368,393,417,447],"$500-$4,999":[346,395,449],"on":[349,373,398,422,452],"Scientific":[351,375,400,424,454],"Advisory":[352,376,401,425,455],"Data":[354,378,403,427,457],"Monitoring":[356,380,405,429,459],"board":[357,381,406,430,460],"Annexon.":[359],"$5,000-$9,999":[370],"UCB":[383],"Pharma.":[384],"ArgenX.":[408],"$10,000-$49,999":[419],"Pfizer.":[432,462,475,486,593,606],"Low":[434],"David":[439],"Hunter":[440],"Glenn":[463,476],"Pixton":[464,477],"Robert":[487,501],"Fountaine":[488,502],"Pfizer,":[499,511],"Lars":[513,526],"Viktrup":[514,527],"Lilly.":[525,536,548],"Elizabeth":[537],"Johnston":[538],"Eli":[547],"Christine":[549,565],"R.":[550,566],"West,":[551,567],"14482":[552,568],"Kenneth":[579,594],"M.":[580,595],"Verburg,":[581,596],"14483":[582,597]},"counts_by_year":[],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2023-12-08T00:00:00"}